SLC5A2 and chronic kidney disease: In addition, these large trials have also documented (as an observational outcome) a clear slowing in the rate of decline in kidney function and reduced incidence of impaired kidney function (39), which has directly led to dedicated studies of SGLT2 inhibitors in people with CKD (detailed below).